Kidney Cancer Therapeutics and Diagnostics Market, Global Outlook and Forecast 2022-2028

April 2022 | 64 pages | ID: K5B5CC319FF5EN
Market Monitor Global

Abstracts

The occurrence of kidney cancer has increased in the recent years. Excessive smoking, rise in obesity because of sedentary life routines and increased consumption of alcohol are some of the causes of kidney cancer. The most common type of cancer is Renal Cell Carcinoma (RCC).Immunotherapies or targeted therapies are the most common prescribed treatments for kidney cancer.

This report contains market size and forecasts of Kidney Cancer Therapeutics and Diagnostics in Global, including the following market information:

Global Kidney Cancer Therapeutics and Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Kidney Cancer Therapeutics and Diagnostics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Cystoscopy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Kidney Cancer Therapeutics and Diagnostics include Bayer, Hoffmann La Roche, GlaxoSmithKline, Novartis, Pfizer, Abbott Laboratories, Amgen, Genentech and Cerulean Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Kidney Cancer Therapeutics and Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Kidney Cancer Therapeutics and Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Kidney Cancer Therapeutics and Diagnostics Market Segment Percentages, by Type, 2021 (%)

• Cystoscopy
• Biopsy
• Intravenous Pyelogram
• CT Scan
• Kidney Ultrasound
• Others

Global Kidney Cancer Therapeutics and Diagnostics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Kidney Cancer Therapeutics and Diagnostics Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Pharmaceutical Labs
• Genomics Laboratories
• Others

Global Kidney Cancer Therapeutics and Diagnostics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Kidney Cancer Therapeutics and Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Kidney Cancer Therapeutics and Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Kidney Cancer Therapeutics and Diagnostics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Bayer
• Hoffmann La Roche
• GlaxoSmithKline
• Novartis
• Pfizer
• Abbott Laboratories
• Amgen
• Genentech
• Cerulean Pharma
• Seattle Genetics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Kidney Cancer Therapeutics and Diagnostics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Kidney Cancer Therapeutics and Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS OVERALL MARKET SIZE

2.1 Global Kidney Cancer Therapeutics and Diagnostics Market Size: 2021 VS 2028
2.2 Global Kidney Cancer Therapeutics and Diagnostics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Kidney Cancer Therapeutics and Diagnostics Players in Global Market
3.2 Top Global Kidney Cancer Therapeutics and Diagnostics Companies Ranked by Revenue
3.3 Global Kidney Cancer Therapeutics and Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Kidney Cancer Therapeutics and Diagnostics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Kidney Cancer Therapeutics and Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Kidney Cancer Therapeutics and Diagnostics Players in Global Market
  3.6.1 List of Global Tier 1 Kidney Cancer Therapeutics and Diagnostics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Kidney Cancer Therapeutics and Diagnostics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Kidney Cancer Therapeutics and Diagnostics Market Size Markets, 2021 & 2028
  4.1.2 Cystoscopy
  4.1.3 Biopsy
  4.1.4 Intravenous Pyelogram
  4.1.5 CT Scan
  4.1.6 Kidney Ultrasound
  4.1.7 Others
4.2 By Type - Global Kidney Cancer Therapeutics and Diagnostics Revenue & Forecasts
  4.2.1 By Type - Global Kidney Cancer Therapeutics and Diagnostics Revenue, 2017-2022
  4.2.2 By Type - Global Kidney Cancer Therapeutics and Diagnostics Revenue, 2023-2028
  4.2.3 By Type - Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Kidney Cancer Therapeutics and Diagnostics Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Pharmaceutical Labs
  5.1.4 Genomics Laboratories
  5.1.5 Others
5.2 By Application - Global Kidney Cancer Therapeutics and Diagnostics Revenue & Forecasts
  5.2.1 By Application - Global Kidney Cancer Therapeutics and Diagnostics Revenue, 2017-2022
  5.2.2 By Application - Global Kidney Cancer Therapeutics and Diagnostics Revenue, 2023-2028
  5.2.3 By Application - Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Kidney Cancer Therapeutics and Diagnostics Market Size, 2021 & 2028
6.2 By Region - Global Kidney Cancer Therapeutics and Diagnostics Revenue & Forecasts
  6.2.1 By Region - Global Kidney Cancer Therapeutics and Diagnostics Revenue, 2017-2022
  6.2.2 By Region - Global Kidney Cancer Therapeutics and Diagnostics Revenue, 2023-2028
  6.2.3 By Region - Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Kidney Cancer Therapeutics and Diagnostics Revenue, 2017-2028
  6.3.2 US Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.3.3 Canada Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.3.4 Mexico Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Kidney Cancer Therapeutics and Diagnostics Revenue, 2017-2028
  6.4.2 Germany Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.4.3 France Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.4.4 U.K. Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.4.5 Italy Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.4.6 Russia Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.4.7 Nordic Countries Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.4.8 Benelux Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Kidney Cancer Therapeutics and Diagnostics Revenue, 2017-2028
  6.5.2 China Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.5.3 Japan Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.5.4 South Korea Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.5.5 Southeast Asia Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.5.6 India Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Kidney Cancer Therapeutics and Diagnostics Revenue, 2017-2028
  6.6.2 Brazil Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.6.3 Argentina Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue, 2017-2028
  6.7.2 Turkey Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.7.3 Israel Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.7.4 Saudi Arabia Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028
  6.7.5 UAE Kidney Cancer Therapeutics and Diagnostics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Bayer
  7.1.1 Bayer Corporate Summary
  7.1.2 Bayer Business Overview
  7.1.3 Bayer Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.1.4 Bayer Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.1.5 Bayer Key News
7.2 Hoffmann La Roche
  7.2.1 Hoffmann La Roche Corporate Summary
  7.2.2 Hoffmann La Roche Business Overview
  7.2.3 Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.2.4 Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.2.5 Hoffmann La Roche Key News
7.3 GlaxoSmithKline
  7.3.1 GlaxoSmithKline Corporate Summary
  7.3.2 GlaxoSmithKline Business Overview
  7.3.3 GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.3.4 GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.3.5 GlaxoSmithKline Key News
7.4 Novartis
  7.4.1 Novartis Corporate Summary
  7.4.2 Novartis Business Overview
  7.4.3 Novartis Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.4.4 Novartis Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.4.5 Novartis Key News
7.5 Pfizer
  7.5.1 Pfizer Corporate Summary
  7.5.2 Pfizer Business Overview
  7.5.3 Pfizer Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.5.4 Pfizer Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.5.5 Pfizer Key News
7.6 Abbott Laboratories
  7.6.1 Abbott Laboratories Corporate Summary
  7.6.2 Abbott Laboratories Business Overview
  7.6.3 Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.6.4 Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.6.5 Abbott Laboratories Key News
7.7 Amgen
  7.7.1 Amgen Corporate Summary
  7.7.2 Amgen Business Overview
  7.7.3 Amgen Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.7.4 Amgen Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.7.5 Amgen Key News
7.8 Genentech
  7.8.1 Genentech Corporate Summary
  7.8.2 Genentech Business Overview
  7.8.3 Genentech Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.8.4 Genentech Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.8.5 Genentech Key News
7.9 Cerulean Pharma
  7.9.1 Cerulean Pharma Corporate Summary
  7.9.2 Cerulean Pharma Business Overview
  7.9.3 Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.9.4 Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.9.5 Cerulean Pharma Key News
7.10 Seattle Genetics
  7.10.1 Seattle Genetics Corporate Summary
  7.10.2 Seattle Genetics Business Overview
  7.10.3 Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Major Product Offerings
  7.10.4 Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
  7.10.5 Seattle Genetics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Kidney Cancer Therapeutics and Diagnostics Market Opportunities & Trends in Global Market
Table 2. Kidney Cancer Therapeutics and Diagnostics Market Drivers in Global Market
Table 3. Kidney Cancer Therapeutics and Diagnostics Market Restraints in Global Market
Table 4. Key Players of Kidney Cancer Therapeutics and Diagnostics in Global Market
Table 5. Top Kidney Cancer Therapeutics and Diagnostics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Kidney Cancer Therapeutics and Diagnostics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Kidney Cancer Therapeutics and Diagnostics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Kidney Cancer Therapeutics and Diagnostics Product Type
Table 9. List of Global Tier 1 Kidney Cancer Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Kidney Cancer Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Kidney Cancer Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Kidney Cancer Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Kidney Cancer Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Kidney Cancer Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 30. Bayer Corporate Summary
Table 31. Bayer Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 32. Bayer Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 33. Hoffmann La Roche Corporate Summary
Table 34. Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 35. Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 36. GlaxoSmithKline Corporate Summary
Table 37. GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 38. GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 39. Novartis Corporate Summary
Table 40. Novartis Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 41. Novartis Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Corporate Summary
Table 43. Pfizer Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 44. Pfizer Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 45. Abbott Laboratories Corporate Summary
Table 46. Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 47. Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 48. Amgen Corporate Summary
Table 49. Amgen Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 50. Amgen Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 51. Genentech Corporate Summary
Table 52. Genentech Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 53. Genentech Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 54. Cerulean Pharma Corporate Summary
Table 55. Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 56. Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 57. Seattle Genetics Corporate Summary
Table 58. Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Product Offerings
Table 59. Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Kidney Cancer Therapeutics and Diagnostics Segment by Type in 2021
Figure 2. Kidney Cancer Therapeutics and Diagnostics Segment by Application in 2021
Figure 3. Global Kidney Cancer Therapeutics and Diagnostics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Kidney Cancer Therapeutics and Diagnostics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Kidney Cancer Therapeutics and Diagnostics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Kidney Cancer Therapeutics and Diagnostics Revenue in 2021
Figure 8. By Type - Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 12. US Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 16. Germany Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 17. France Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 24. China Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 28. India Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 30. Brazil Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Kidney Cancer Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 33. Turkey Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Kidney Cancer Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 37. Bayer Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novartis Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Amgen Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Genentech Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)